Note: DESTINY-Breast06: HR-positive HER2-low or HER2-ultralow breast cancer after endocrine therapy, adjudicated drug-induced ILD, ENHERTU n=434 vs chemotherapy n=417 (table columns are Grades 1 to 5 and all grades). DESTINY-Breast04: HER2-low breast cancer after chemotherapy, HR-positive and HR-negative patients, ENHERTU n=371. The last passage is the pooled safety population of the Prescribing Information (2233 patients with several tumor types treated with 5.4 mg/kg).
Does Enhertu cause neutropenia (low neutrophil count)?
Note: The second passage is the pooled safety population (2233 patients with several tumor types treated with 5.4 mg/kg). The DESTINY-Breast06 row gives all grades and Grades 3-4 for ENHERTU (n=434), then all grades and Grades 3-4 for chemotherapy (n=417), as percentages.
Does Enhertu cause heart problems (left ventricular dysfunction)?
Note: The DESTINY-Breast06 row gives all grades and Grades 3-4 for ENHERTU (n=434), then all grades and Grades 3-4 for chemotherapy (n=417), as percentages.
Side effects
What are the most common Enhertu side effects in HER2-low or HER2-ultralow breast cancer?
Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)
Note: Rates are from the DESTINY-Breast06 safety population (ENHERTU n=434; HR-positive HER2-low or HER2-ultralow breast cancer after endocrine therapy).
How do Enhertu side effects compare with chemotherapy in DESTINY-Breast06?
Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)
Note: Columns, in order: ENHERTU 5.4 mg/kg (n=434) all grades and Grades 3-4, then chemotherapy (physician's choice of capecitabine, nab-paclitaxel, or paclitaxel; n=417) all grades and Grades 3-4, as percentages. Several terms group related events, as defined in the footnotes on the source page.
What were the most common Enhertu side effects in DESTINY-Breast04?
Applies to Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)
Note: Rates are from the DESTINY-Breast04 safety population (ENHERTU n=371; HER2-low breast cancer after chemotherapy, HR-positive and HR-negative patients).
How often were Enhertu side effects serious or fatal in DESTINY-Breast06?
Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)
Note: DESTINY-Breast06. In the table rows, the first percentage is ENHERTU (n=434) and the second is chemotherapy (physician's choice of capecitabine, nab-paclitaxel, or paclitaxel; n=417).
How often did patients stop or reduce Enhertu because of side effects (DESTINY-Breast06)?
Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)
Note: DESTINY-Breast06. In the table rows, the first percentage is ENHERTU (n=434) and the second is chemotherapy (physician's choice of capecitabine, nab-paclitaxel, or paclitaxel; n=417).
How often were Enhertu side effects serious or fatal in DESTINY-Breast04?
Applies to Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)
Note: DESTINY-Breast04 safety population: HER2-low breast cancer after chemotherapy, HR-positive and HR-negative patients. In the table rows, the first percentage is ENHERTU (n=371) and the second is physician's choice chemotherapy (eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel; n=172).
How often did patients stop or reduce Enhertu because of side effects (DESTINY-Breast04)?
Applies to Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)
Note: DESTINY-Breast04 safety population: HER2-low breast cancer after chemotherapy, HR-positive and HR-negative patients. In the table rows, the first percentage is ENHERTU (n=371) and the second is physician's choice chemotherapy (eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel; n=172).
Does Enhertu cause hair loss?
Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)
Note: DESTINY-Breast06. First row: ENHERTU (n=434) all grades and Grades 3-4, then chemotherapy (n=417) all grades and Grades 3-4, as percentages. Second row: ENHERTU Grades 1, 2, 3, and 4, as percentages.